Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Diluted Average) (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 0.71% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, up 0.71% year-over-year, with the annual reading at $30.0 million for FY2025, 0.71% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $30.0 million in Q4 2025 for Krystal Biotech, roughly flat from $29.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $30.0 million in Q4 2025 to a low of $21.3 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $26.7 million across 5 years, with a median of $26.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 18.17% in 2022 and later rose 0.54% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $22.2 million in 2021, then increased by 14.85% to $25.5 million in 2022, then grew by 8.87% to $27.8 million in 2023, then rose by 7.16% to $29.7 million in 2024, then increased by 0.71% to $30.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for KRYS at $30.0 million in Q4 2025, $29.8 million in Q3 2025, and $29.8 million in Q2 2025.